B-Cell Biomarker Panel for Allergen Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic diseases, such as allergen immunotherapy, face challenges in predicting treatment response and disease progression due to poor patient adherence and adverse reactions, with existing biomarkers being expensive and not universally effective.
Innovation Solution
A method for determining allergen immunotherapy efficacy by measuring specific biomarkers in B-cells, including IgE, CD29, CD69, IL13Rα, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CD1c, CD23, and IL4Rα, through sample analysis before and after treatment, indicating efficacy based on fold changes in marker levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allergen immunotherapy is administered for long term repeated exposure, then treatment efficacy is improved, but patient adherence deteriorates due to poor compliance and adverse reactions
Solution Approach 1:
The patent applies preliminary action by measuring baseline biomarker levels (such as IgE, CD23, CD69) in B-cells before initiating allergen immunotherapy. This allows prediction of treatment response in advance, enabling patients and clinicians to assess likelihood of success before committing to long-term therapy, thereby improving adherence by setting realistic expectations and identifying suitable candidates upfront.
Solution Approach 2:
The patent implements feedback by monitoring changes in B-cell biomarker levels during and after allergen immunotherapy. By tracking biomarker dynamics (e.g., decreases in CD69, CD23, or IgE levels), the system provides objective feedback on treatment efficacy, allowing clinicians to adjust therapy duration and dosing to optimize both efficacy and patient adherence.
2Measurement precision
If existing biomarkers are used to predict treatment response, then measurement capability is improved, but cost increases and universal effectiveness deteriorates
Solution Approach 1:
The patent applies universality by developing a multi-marker panel that assesses multiple B-cell biomarkers (IgE, CD23, CD69, CD99, FCRL3, SIGLEC10, IL4Rα) simultaneously. This comprehensive panel is designed to be universally applicable across different allergen types and patient populations, improving universal effectiveness while maintaining measurement precision through the collective information from multiple markers.
Solution Approach 2:
The patent employs parameter changes by focusing on specific B-cell surface marker expressions and their dynamic changes during therapy. By measuring relative changes in biomarker levels (fold-changes) rather than absolute values, the approach adapts to individual patient baselines, enhancing universal applicability across diverse populations while maintaining precise treatment response prediction.
Data Source
AI summary
The present invention relates to the field of medical diagnostics. In particular, it relates to methods and kits for determining treatment efficacy of allergen immunotherapy, and for measuring or detecting biomarkers in a subject undergoing allergen immunotherapy. For example, the invention provides a method of determining efficacy of an allergen immunotherapy in a subject, the method comprising: providing a first sample obtained from a subject before receiving allergen immunotherapy; providing a second sample obtained from the subject who has received, or who is receiving, allergen immunotherapy; wherein the first and second samples comprise B-cells; and determining the level or amount of one or more biomarkers in B-cells, preferably allergen-specific B-cells, in the first and second samples, wherein the biomarkers are selected from the group consisting of IgE, CD29, CD69, IL13Rα, CD99, IgD, CXCR4, FCRL3, FCRL2, FCRL5, SIGLEC10, CDIc, CD23, and IL4Rα; wherein an increase in the level or amount of one or more biomarkers selected from IgE, CD29, IL13Rα, CD99, FCRL3, FCRL2, SIGLEC10, CD1c, CD23, and IL4Rα in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject, and/or wherein a decrease in the level or amount of one or more biomarkers selected from CD69, IgD, CXCR4, FCRL3, FCRL2, FCRL5, CD1c, CD23, IL4Rα in B-cells in the second sample compared to the first sample indicates efficacy of an allergen immunotherapy in a subject.